- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00053872
Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma
A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving radiation therapy in different ways with combination chemotherapy may kill any remaining tumor cells following surgery. It is not yet known which radiation therapy regimen combined with combination chemotherapy is more effective in treating medulloblastoma.
PURPOSE: Randomized phase III trial to compare different radiation therapy regimens plus combination chemotherapy in treating children who have undergone surgery for medulloblastoma.
Studienübersicht
Status
Detaillierte Beschreibung
OBJECTIVES:
- Compare the event-free survival rate in pediatric patients with standard-risk medulloblastoma treated with conventional vs hyperfractionated radiotherapy and vincristine followed by maintenance with cisplatin, lomustine, and vincristine.
- Compare the overall survival of patients treated with these regimens.
- Compare the pattern of relapse, especially local relapse (tumor bed or posterior fossa outside tumor bed), in patients treated with these regimens.
- Determine the toxicity of surgery and whether there are identifiable factors that correlate with toxicity in these patients.
- Determine the impact of any surgical complications on commencement of adjuvant therapy and event-free survival of these patients.
- Compare late sequelae, in terms of health status, endocrine deficiencies, and hearing loss, in patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to country. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Within 28-40 days after surgical resection, patients undergo conventional fractionated radiotherapy once daily, 5 days a week, for 6-7 weeks. Patients also receive vincristine IV once weekly for 8 weeks.
- Arm II: Beginning as in arm I, patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, for 6-7 weeks. Patients also receive vincristine as in arm I.
- Maintenance chemotherapy:Six weeks after completion of radiotherapy, all patients receive cisplatin IV over 6 hours and oral lomustine on day 1 and vincristine IV on days 1, 8, and 15. Treatment repeats every 6 weeks for 8 courses.
Patients are followed at least every 6 months for 3 years.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 316 patients (158 per treatment arm) will be accrued for this study within 4 years.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Leuven, Belgien, B-3000
- U.Z. Gasthuisberg
-
-
-
-
-
Wuerzburg, Deutschland, D-97080
- Universitaets - Kinderklinik Wuerzburg
-
-
-
-
-
Paris, Frankreich, 75248
- Institut Curie Hopital
-
-
-
-
-
Turin, Italien, 10126
- Ospedale Infantile Regina Margherita
-
-
-
-
-
Amsterdam, Niederlande, 1105 AZ
- Academisch Medisch Centrum at University of Amsterdam
-
-
-
-
-
Gothenburg, Schweden, 41685
- Östra sjukhuset
-
-
-
-
-
Vizcaya, Spanien, 48
- Hospital de Cruces
-
-
-
-
England
-
Liverpool, England, Vereinigtes Königreich, L12 2AP
- Royal Liverpool Children's Hospital, Alder Hey
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Histologically confirmed medulloblastoma, including the following variants:
- Classic
- Nodular/desmoplastic
- Large cell
- Melanotic
- Medullomyoblastoma
Prior total or subtotal surgical removal of tumor within the past 28-40 days
- No more than 1.5 cm^2 residual tumor by early postoperative MRI or CT scan
- No brainstem or supratentorial primitive neuroectodermal tumor
- No atypical teratoid rhabdoid tumor
- No known predisposition to medulloblastoma (e.g., Gorlin's syndrome)
- No CNS metastasis (supratentorial, arachnoid of the posterior fossa, or craniospinal axis) by MRI
- No clinical evidence of metastasis outside the CNS
- No tumor cells in lumbar cerebrospinal fluid by cytospin
PATIENT CHARACTERISTICS:
Age
- 3 to 21
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Hematological function less than CTC grade 2
Hepatic
- Liver function less than CTC grade 2
Renal
- Renal function less than CTC grade 2
Other
- Not pregnant
- Fertile patients must use effective contraception
- Able to receive radiotherapy twice daily
- Vital functions within age-appropriate normal range
- Audiological function less than CTC grade 2
- No medical contraindication to radiotherapy or chemotherapy
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Concurrent dexamethasone as an antiemetic allowed, provided all other therapies have failed
Radiotherapy
- No concurrent cobalt irradiation
Surgery
- See Disease Characteristics
Other
- No prior treatment for brain tumor or any other malignancy
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
---|
Comparison of event-free survival at 3 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
---|
Comparison of overall survival
|
Comparison of the pattern of relapse (i.e., local relapse [tumor bed and posterior fossa outside tumor bed])
|
Comparison of late sequelae, in terms of health status, quality of life, hearing loss, and endocrine deficiencies
|
Toxicity of neurosurgery
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: Brigitta Lannering, MD, PhD, Östra sjukhuset
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Nervensystems
- Neubildungen nach histologischem Typ
- Neubildungen
- Neubildungen nach Standort
- Neubildungen, Drüsen und Epithelien
- Gliom
- Neubildungen, Neuroepithel
- Neuroektodermale Tumoren
- Neoplasmen, Keimzelle und Embryonal
- Neubildungen, Nervengewebe
- Neuroektodermale Tumore, primitiv
- Neubildungen des Nervensystems
- Neubildungen des zentralen Nervensystems
- Medulloblastom
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antineoplastische Mittel
- Tubulin-Modulatoren
- Antimitotische Mittel
- Mitose-Modulatoren
- Antineoplastische Mittel, alkylierend
- Alkylierungsmittel
- Antineoplastische Mittel, Phytogen
- Cisplatin
- Vincristin
- Lomustin
Andere Studien-ID-Nummern
- CDR0000269521
- SIOP-PNET-4
- EU-20244
- UKCCSG-CNS-2003-05
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Strahlentherapie
-
Alpha Tau Medical LTD.Noch keine RekrutierungBrustkrebs | Brustkrebs | Rezidivierender BrustkrebsIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Hauttumor | Kutane MetastasenFrankreich
-
Alpha Tau Medical LTD.European Organisation for Research and Treatment of Cancer - EORTCNoch keine RekrutierungKopf-Hals-Plattenepithelkarzinom | PlattenepithelkarzinomIsrael
-
Alpha Tau Medical LTD.RekrutierungProstata-AdenokarzinomIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaIsrael
-
Alpha Tau Medical LTD.RekrutierungLungenkrebs | Wiederkehrender LungenkrebsIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaIsrael
-
Alpha Tau Medical LTD.AbgeschlossenPlattenepithelkarzinomIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaItalien
-
Alpha Tau Medical LTD.Aktiv, nicht rekrutierendHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaIsrael